Trophoblastic Neoplasms

CHESTER, N.J., July 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology. Continue Reading Nana E, Tchabo, MD, FACOG Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience and a minor in Women's Studies. She then attended the Warren Alpert Brown University School of Medicine, where she was cited for academic excellence. The doctor completed a residency in Obstetrics and Gynecology at Georgetown University; a research fellowship in ovarian cancer and molecular techniques at the National Cancer Institute; and a Fellowship in Gynecologic Oncology at Roswell Park Cancer Institute in Buffalo. Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health System Morristown and Overlook Medical Centers. As part of her responsibilities, the doctor coordinates unified, comprehensive care integrating various treatments including minimally invasive surgery; chemotherapy; radiation therapy; along with supportive care services. Focused on prevention and survivorship, Dr. Tchabo is a Principal Investigator on many of the gynecologic cancer clinical research trials available at the Carol G. Simon Cancer Center and serves as Associate Residency Director for Gynecology at Overlook Medical Center. She is also an Assistant Clinical Professor at Sidney Kimmel Medical College of Thomas Jefferson University. Her prior appointments include Assistant Clinical Professor at Mount Sinai School of Medicines' Department of Obstetrics, Gynecology, and Reproductive Science. Board-certified in both Obstetrics and Gynecology & Gynecologic Oncology by the American Board of Obstetrics and Gynecology (ABOG), Dr. Tchabo notes that the mission of the ABOG is to define specialty standards; certify obstetricians and gynecologists; and facilitate continuous learning to advance knowledge; practice; and professionalism in women's health. She explained that gynecologic oncology is a specialized field of medicine that focuses on cancers of the female reproductive system, including ovarian cancer; uterine cancer; vaginal cancer; cervical cancer; vulvar cancer; gestational trophoblastic disease, and preinvasive conditions. A Gynecologic Oncologist, like Dr. Tchabo, is a physician who specializes in treating women with reproductive tract cancers. They are initially trained as Obstetrician/Gynecologists and then undergo three to possibly more than five years of specialized education in all the effective forms of treatment for gynecologic cancers (surgery; radiation; chemotherapy; immunotherapy; and clinical research trials) as well as the biology and pathology of gynecologic cancers. Dedicated to her local community, Dr. Tchabo is a member of Delta Sigma Theta Sorority, Inc. and Jack & Jill of America, Inc.. She is engaged in community service initiatives and fosters leadership skills in African-American youth. Dr. Tchabo has received many accolades during her career including Exceptional Women In Medicine: 2019, 2020, 2021, 2022, 2023; Jerseys Best Magazine Top Doctors: 2019, 2020, 2021, 2022; Jerseys Best Top Doctors for Cancer: 2019, 2021, 2022; Top Doctors New York Metro Area (digital guide): 2018, 2019, 2020, 2021, 2022; New York Magazine: Top Doctors: 2021, 2022; and Jerseys Best Top Doctors for Women's Health: 2021, 2022, and New Jersey Monthly Top Doctors: 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023. She would like to dedicate this honor to her parents: Jean-Gilles Tchabo, MD and Elizabeth Anne Robertson-Tchabo, PhD. The doctor has been married to Charles desBordes, Ph.D. for 17 years and they have 2 sons. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle

Researchers have designed a new genetic therapy that could alleviate debilitating giant moles in a rare skin condition. Researchers at the Francis Crick Institute, UCL Great Ormond Street Institute for Child Health and Great Ormond Street Hospital for Children (GOSH) have designed a new genetic therapy that could alleviate debilitating giant moles in a rare skin condition. In the future, the treatment could potentially be used to reverse the giant moles, and therefore reduce the risk of affected children and adults from developing cancer. It could also potentially reverse other more common types of at-risk moles as an alternative to surgery. Small skin moles are common in the population, but in congenital melanocytic naevus syndrome (CMN), children are born with up to 80% of their body covered in big, painful or itchy moles, caused by mutations acquired in the womb. These moles can sometimes develop into a severe type of cancer called melanoma. Published today in the Journal of Investigate Dermatology, the researchers silenced a gene called NRAS, which is mutated in the cells in these moles, in cells in a dish and in mice. NRAS belongs to a group of genes (RAS genes) that, when mutated, can cause moles, and can predispose to cancer. The team used a genetic therapy called silencing RNA, which silences the mutated NRAS in mole skin cells. The therapy was delivered in special particles directly to mole cells. They gave injections containing the therapy to mice with CMN, which reduced the silenced the NRAS gene after just 48 hours. They also tested it in cells and whole skin sections from children with CMN. Silencing the gene triggered the mole cells to self-destruct. Veronica Kinsler, Principal Group Leader of the Mosaicism and Precision Medicine Laboratory at the Crick, Professor of Paediatric Dermatology and Dermatogenetics at GOSH/UCL, and NIHR Research Professor, said: "CMN is physically and mentally challenging for children and adults living with this condition and for their families. These results are very exciting, as not only does the genetic therapy trigger self-destruction of the mole cells in the lab, but we have managed to deliver it into the skin in mice. This results suggest that the treatment in future could potentially reverse moles in people, however more testing will be needed before we can give it to patients. "We are very grateful to our patients at Great Ormond Street Hospital, who have been actively participating over many years to help us produce this new potential therapy. After more studies, we hope the therapy can soon enter clinical trials in people." This research was funded by the National Institute for Health and Care Research (NIHR), Caring Matters Now Charity and Patient Support Group, LifeArc and the NIHR Great Ormond Street Hospital Biomedical Research Centre. Jodi Whitehouse, CEO of Caring Matters Now, who helped to fund the research, said: "This breakthrough in finding a treatment for CMN could transform the lives of the families we support living with CMN. As someone who was born with CMN covering 70% of my body and having undergone 30+ operations in my childhood to try and remove the CMN because of the fear of melanoma, with no success, this news is awe-inspiring and exciting. It brings real hope to the lives of those living with CMN." Catriona Crombie, Head of Rare Disease at LifeArc, said: "This work is part of our commitment to improving the lives of people living with rare diseases, by investing in promising research and helping scientists to overcome translational research barriers. If successful, we hope to see human clinical trials for this therapy within the next few years." The researchers have been working closely with the Crick's Translation team to develop the technology towards patient benefit. This has included securing translational funds from LifeArc, to carry out more research in mice to understand how the treatment works over a longer period.

Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3) clinical trial has been selected for presentation at the “Best Oral Session – Late Breaking Abstracts” on Sunday, March 10, 2024 at the European Society on Gynaecological Oncology (ESGO) 2024 Congress in Barcelona. The randomized, phase 3 INNOVATE-3 clinical trial evaluated the use of Tumor Treating Fields (TTFields) therapy together with paclitaxel in platinum-resistant ovarian cancer (PROC) in patients with a maximum of five total prior lines of systemic therapy. While the INNOVATE-3 study did not meet its primary endpoint of overall survival in the intent-to-treat population, an exploratory analysis of a subgroup from the trial concluded that PLD-naïve patients treated with TTFields therapy and paclitaxel saw a significant improvement in overall survival compared to PLD-naïve patients treated with paclitaxel alone. Of the 558 total patients enrolled in the INNOVATE-3 clinical trial, 201 patients (36%) were PLD-naïve. Overall survival in PLD-naïve patients randomized to receive TTFields therapy and paclitaxel was 16.0 months (n=113), compared to 11.7 months in PLD-naïve patients randomized to receive paclitaxel alone (n=88). In the PLD-naïve subgroup, baseline demographics were similar across both cohorts. Novocure is further exploring the effect of doxorubicin on tumor tissue alteration and the potential consequences for TTFields dose. The findings from this post-hoc analysis may help explain the potential survival benefit observed in INNOVATE-3 patients who received only one prior line of therapy, as previously reported. TTFields therapy was well-tolerated, and no additive systemic toxicity or safety signals were observed. “We are extremely pleased to share these data with our colleagues at ESGO and humbled by the selection for a best oral presentation session,” said primary investigator Professor Ignace Vergote, MD, PhD, Professor at the Catholic University of Leuven, Belgium. “There is an immense clinical need for safe, effective and less toxic therapies for PROC patients and I look forward to continued exploration of TTFields therapy in gynecological cancers.” “The presentation of these data is an exciting achievement for the INNOVATE-3 investigators, as well as the Novocure team, reflecting exceptional work, collaboration and dedication,” said Nicolas Leupin, MD, PhD, Novocure’s Chief Medical Officer. “I would like to thank our collaborators, ENGOT and The GOG Foundation, for their partnership designing and conducting the INNOVATE-3 trial. These findings provide valuable new insights, and we are eager to continue exploring the capabilities of TTFields therapy in the treatment of solid tumors.” The exploratory analysis from the INNOVATE-3 data will be presented on Sunday, March 10, 2024 at 11:50 a.m. UTC+1 by Professor Vergote, and has been selected for inclusion in the “Best Oral Session – Late Breaking Abstracts” as part of the European Society on Gynaecological Oncology (ESGO) annual congress. About ENGOT-ov50 / GOG-3029 / INNOVATE-3 The ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial was designed to evaluate the safety and effectiveness of TTFields together with paclitaxel in patients with platinum-resistant ovarian cancer and a maximum of five total prior lines of systemic therapy. The primary endpoint of INNOVATE-3 was overall survival. Secondary endpoints include progression-free survival, objective response rate, severity and frequency of adverse events, time to undisputable deterioration in health-related quality of life or death, and quality of life. Enrollment in the trial closed in October 2021 with 558 patients enrolled, beginning the minimum 18-month follow-up period. In 2023, Novocure announced the trial did not meet its primary endpoint. Together with investigators, the company will continue to analyze the data from the INNOVATE-3 trial. The European Network for Gynaecological Oncological Trial groups ("ENGOT") and The GOG Foundation, Inc. ("GOG"), third-party clinical trial networks, collaborated with Novocure on the trial. Both ENGOT and GOG were involved in the development and facilitation of the trial at leading cancer centers in Europe and the United States. About Ovarian Cancer In the U.S., ovarian cancer ranks fifth in cancer deaths among women, with approximately 24,000 women diagnosed each year. Ovarian cancer incidence increases with age, and the median age at time of diagnosis is 63 years old. Physicians use different combinations of surgery and pharmacological therapies to treat ovarian cancer, depending on the stage of the disease. Surgery is usually used in early stages of the disease and is usually combined with chemotherapy, including paclitaxel and platinum-based chemotherapy. Unfortunately, the majority of patients are diagnosed at an advanced stage when the cancer has spread outside of the ovaries to include regional tissue involvement and/or metastases. Platinum-based chemotherapy remains part of the standard of care in advanced ovarian cancer, but most patients with advanced ovarian cancer will have tumor progression or, more commonly, recurrence. Almost all patients with recurrent disease ultimately develop platinum resistance, and the prognosis for this population remains poor. About Tumor Treating Fields Therapy Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or PARP inhibition in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com. About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter. About ENGOT and BGOG ( and ) The European Network of Gynaecological Oncology Trial groups (ENGOT) is a platform that guarantees that the European spirit and culture is incorporated into the medical progress in gynaecological oncology, and that all European patients and countries can participate in an active way in clinical research and progress. The ultimate goal is to bring the best treatment to gynecological cancer patients through the best science and enabling every patient in every European country to access a clinical trial. The Belgium and Luxembourg Gynaecological Oncology Group (BGOG) is one of the founding study groups of ENGOT. About The GOG Foundation, Inc. (GOG-F) ( ) The GOG Foundation, Inc. is a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and translational scientific research in the field of gynecologic malignancies. The GOG Foundation is committed to maintaining the highest standards in clinical trials development, execution, analysis, and distribution of results. The GOG Foundation is the only clinical trialist group in the United States that focuses its research on patients with pelvic malignancies, such as cancer of the ovary (including surface peritoneal malignancies), uterus (including endometrium, soft tissue sarcoma, and gestational trophoblastic neoplasia), cervix, and vulva. The GOG Foundation is multi-disciplinary in its approach to clinical trials, and includes gynecologic oncologists, medical oncologists, pathologists, radiation oncologists, oncology nurses, biostatisticians (including those with expertise in bioinformatics), basic scientists, quality of life experts, data managers, and administrative personnel. About GOG Partners Program Supported by industry, GOG Partners is structured to work directly with pharmaceutical organizations and operate clinical trials outside the National Cancer Institute (NCI) framework. The GOG Partners Program shares the same mission of the GOG Foundation dedicated to transforming the care in Gynecologic Oncology. By providing an alternative venue for patient accrual and site infrastructure support, GOG Partners has helped provide additional trials and opportunities for patients outside the national gynecologic clinical trials network. Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “could” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion. View source version on businesswire.com: Contacts Investors: Ingrid Goldberg investorinfo@novocure.com media@novocure.com 610-723-7427 Source: Novocure View this news release online at: